Just two weeks after receiving approval from the FDA to begin testing an inhaled formulation of their remdesivir COVID-19 treatment, Gilead kicked off a trial comprised of 60 healthy participants. The drug, given in intravenous form has shown promise, but the effects of the inhaled dosage form targeting less severe cases are still unknown. Yourway offers end-to-end protection on shipment distribution and flexible options, including direct-to-patient services, to ensure drugs in trials reach their destinations as soon as possible.
6681 Snowdrift Road
Toll Free:
Fax:
Email:
